Finally, T cell therapy with KRASG12D-targeting T cell receptors (TCRs) caused tumor regression in a patient with pancreatic cancer, and T cells with TCRs targeting other KRAS mutations, such KRASG12V, are under development22,23. Here, KRAS is linked to pancreatic neoplasm.